On January 14, 2015, Bertech Diagnostics Ltd. (an enterprise of "The Bertech Group”) announced the signing of a license agreement with Global Cancer Diagnostics of Tempe, Arizona. This agreement enables Bertech to sell The Lung Cancer Test™ in Canada. With this partnership The Lung Cancer TestTM will continue its rapid expansion for use by current and former smokers. The Lung Cancer Test was introduced to the U.S. marketplace in late 2014.
The Lung Cancer Test™ can be utilized for annual screening for Lung Cancer in current and former smokers. The Test has been clinically proven to detect Lung Cancer in its early stages. With early detection comes early treatment and higher survival rates.
Bertech is addressing the need for patient-friendly, accurate and inexpensive diagnostic tests in Canada. They are located in Edmonton, Alberta and will utilize partnerships with laboratories throughout Canada to provide the test to Canadians. The Lung Cancer Test™ will be a complement to Bertech's line of colorectal cancer diagnostics and treatments. Information on The Lung Cancer Test™ in Canada can be obtained by contacting Bertech at email@example.com.
All required Clinical and Validation studies have been completed with excellent results. The Test detects the presence of the required biomarkers that are proven effective in the early detection of lung cancer. The Test is now available in all U.S. states. The Lung Cancer Test™ is intended for use in the high-risk patient population which includes current and former smokers over the age of 50. Global Cancer Diagnostics Inc. announced that The Lung Cancer Test™ was available for purchase beginning late last year. This information was publicized on Herald Online.
About Bertech Diagnostics Ltd.
Bertech Diagnostics Ltd. (“Bertech”) is a privately held biotechnology company located in Edmonton, Canada. Bertech and its affiliated enterprises (“The Bertech Group”) develop and distribute innovative, leading edge tools for the diagnosis and treatment of cancer. Bertech’s goal is to advance diagnosis, assessment and treatment options for clinicians, which will improve outcomes for patients. Development of their leading edge biomarker assays and their new treatment compounds will increase early detection and improve treatment selection and assessment.
In addition to ensuring the Canadian market has access to Global Cancer Diagnostic’s innovative The Lung Cancer Test™, Bertech currently has in development a novel blood test for the diagnosis of colorectal cancer, an ELISA assay for monitoring a patient’s immune response to colorectal cancer treatments, along with several new cancer compounds which are in preclinical development. These compounds are structurally divergent from established drugs, are devoid of the genotoxic properties of many contemporary anti-cancer drugs, and will reverse multi-drug resistance.